2024-09-30 - Analysis Report
## Amgen Inc (AMGN) Stock Analysis Report

**Company Overview:** Amgen is a leading biotechnology company that develops and manufactures innovative human therapeutics.

**1. Performance Comparison:**

* **Cumulative Return:** AMGN (83.64%) has underperformed the S&P 500 (VOO, 133.28%) by -49.64% since inception.
* **Relative Outperformance:** The current relative outperformance of AMGN compared to VOO is 36.28%, indicating that AMGN's performance has been better than VOO during 36.28% of the time in its historical data range.

**2. Recent Price Movements:**

* **Closing Price:** $327.7
* **5-Day Moving Average:** $325.69
* **20-Day Moving Average:** $329.47
* **60-Day Moving Average:** $328.14
* **Current price is slightly below its 20-day and 60-day moving averages, suggesting some short-term downward pressure.**

**3. Technical Indicators:**

* **RSI:** 51.56 - Indicates a neutral market condition, neither overbought nor oversold.
* **PPO:** -0.38 - Suggesting potential weakness in the price trend, but not significantly bearish.
* **Delta_Previous_Relative_Divergence:** -6.98 - Shows a short-term downward trend in the relative strength of AMGN compared to its recent historical performance.
* **Expected_Return:** 0.0% - This figure represents the maximum expected return over a 5-year period, based on current investment amounts.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

**The most recent earnings report (2024-08-07) showed EPS of $1.39, exceeding analysts' expectations.**  The company's revenue also surpassed estimates, reaching $8.39 billion.  This positive earnings beat demonstrates strong growth and potential for future success.

**5. News and Recent Issues:**

Recent market outlook for AMGN remains positive. Analyst opinions are generally bullish, with several analysts highlighting the company's strong pipeline, innovative product development, and market leadership in biopharmaceuticals.  Analysts anticipate continued growth driven by existing products and new drug launches.

**6. Overall Analysis:**

AMGN is a solid company with a strong market position, a positive recent earnings report, and a promising outlook. However, it's important to note that the stock has underperformed the market in recent years. The current technical indicators suggest potential for short-term weakness, but overall the outlook remains positive. Investors should closely monitor upcoming earnings reports and industry developments to evaluate the long-term potential of AMGN.

**7. Final Thoughts:**

AMGN remains a strong contender in the biotechnology industry. Its recent earnings performance and positive market outlook make it a promising investment opportunity. However, it is important to monitor the stock's performance closely and consider its recent underperformance compared to the market.

**Please note that this analysis is for informational purposes only and should not be considered financial advice. It is crucial to conduct thorough research and consult with a qualified financial advisor before making any investment decisions.**